4 / 30
Pembrolizumab KEYTRUDA
(anti-PD-1)
Nivolumab
OPDIVO
(anti-PD-1)
Durvalumab
(anti-PD-L1)
Atezolizumab
TECENTRIQ
(anti-PD-L1)
Avelumab
BAVENCIO
(anti-PD-L1)
Clone
22C3
SP263
28-8
SP263
SP263
SP142
73-10
PD-L1 domain
Extracellular N-terminus,
humanised IgG4
Cytoplasmic C-terminus,
human Fc-modifed IgG1
Extracellular N-terminus,
human IgG4
Cytoplasmic C-terminus,
human Fc-modifed IgG1
Cytoplasmic C-terminus,
human Fc-modifed IgG1
Cytoplasmic C-terminus,
human Fc-modifed IgG1
Extracellular N-terminus,
human IgG4
Type
Mouse monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Rabbit monoclonal
Diagnostic Partner
Dako
Ventana
Dako
Ventana
Ventana
Ventana
Dako
Platform
Autostainer Link
Optiview Benchmark Ultra
Autostainer Link
Optiview Benchmark Ultra
Optiview Benchmark Ultra
Optiview and amplification
Benchmark Ultra
Autostainer Link
Approval status
Companion diagnostics
Companion diagnostics
Complementary
Complementary
In development
Complementary
In development
Compartment
Tumor cell (TC)
Tumor cell (TC)
Tumor cell (TC)
Tumor cell (TC)
Tumor cell (TC)
Tumor (TC), Immune
cells (IC)
Tumor cell (TC)
NSCLC clinical trials
KEYNOTE001 (Phase I),
KEYNOTE010 (Phase III)
CheckMate057 (Phase I),
CheckMate063 (Phase
II), CheckMate017
(Phase III)
NCT01693562
POPLAR (Phase II),
BIRCH (Phase II)
Javelin (Phase I)
Biomarker cut-off for
PD-L1 positivity
≥50% TC
≥1% TC
≥50% TC
≥1% TC
≥1% TC
≥1% TC
≥25% TC
TC3/IC3: TC ≥50% or IC
≥10%
TC2/IC2: : TC or IC ≥5%
TC1/IC1: TC or IC ≥1%
≥1% TC
PD-L1 assays for immune
checkpoint inhibitors in NSCLC